Announcement on Shareholding Reduction Plan for Shareholders with Over 5% Shares
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
Link of Full Text for Reference:
Announcement on Shareholding Reduction Plan for Shareholders with Over 5% Shares
Filed with SSE · · 5 pages · Chinese
Release
Shanghai Junshi Biosciences Co., Ltd. on 6ix
Earlier from Shanghai Junshi Biosciences
- Announcement on Voluntary Disclosure of the FDA Approval of Clinical Trial Application for JS212
- Announcement on Voluntary Disclosure of New Indication of Tuoyi® and the Inclusion of Junshida® in the National Medical Insurance Catalog
- Junshi Biosciences Announces Acceptance of the NDA for Roconkibart (IL-17A) for the Treatment of Moderate to Severe Plaque Psoriasis
- Toripalimab Presents Long-Term Survival Benefits as 1st-line Treatment for Advanced Nasopharyngeal Carcinoma and Esophageal Squamous Cell Carcinoma Patients
- Announcement on Result of Shareholding Reduction by Shareholder with Over 5% Shares
Later from Shanghai Junshi Biosciences
- Announcement on Receipt of the "Notice of Registration Acceptance" from the National Association of Financial Market Institutional Investors
- Announcement on Postponing Investment Projects Financed by Raised Funds
- Announcement on the Results of Issuance of the 2026 Phase I Science and Technology Innovation Bonds
- Earnings Preannouncement for 2025
- Junshi Biosciences Announces Strategic Collaboration with Antengene to Evaluate Combination Therapy with JS207 (PD-1/VEGF BsAb) and ATG-037 (Oral CD73 Inhibitor)
Follow Shanghai Junshi Biosciences into a list and get an email when it puts out news.
Follow Shanghai Junshi Biosciences